Methods, markers, and test kits for testing cancer in carnivores, and screening methods for prophylactic and ameliorative agents for cancer in carnivores.
The GH20 gene and pks islands are used as indicators for rapid and inexpensive cancer detection in carnivorous animals, addressing the need for early cancer detection without stress, enhancing diagnostic capabilities and treatment initiation.
Patent Information
- Application Number
- JP2025078768
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-19
AI Technical Summary
Current technologies do not adequately support early detection of cancer in Carnivora animals without causing stress and are not cost-effective or rapid.
Utilizing the GH20 gene from Bacteroides fragilis and pks islands as indicators, detected through PCR, to assess the likelihood of cancer in carnivorous animals using non-invasive samples like feces, saliva, or blood, allowing for rapid and inexpensive cancer testing.
Enables early detection of cancer in Carnivora animals, reducing the burden on animals and their owners, facilitating prompt treatment and improving treatment outcomes.
Smart Images

Figure 2026182489000001_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method, marker and test kit for testing cancer in Carnivora animals, as well as a screening method for a preventive or ameliorating agent for cancer in Carnivora animals.
Background Art
[0002] Carnivora includes representative companion animals such as dogs and cats. Along with the increased longevity brought about by recent advances in medical technology and improvements in breeding environments, the number of cases of these companion animals suffering from cancer is increasing. Cancer is generally a disease for which a favorable prognosis can be expected through early detection and early treatment. Accordingly, a technology capable of early detection of cancer in Carnivora animals is highly desired. For example, Patent Document 1 discloses a method for detecting urothelial carcinoma or prostate cancer, which uses the copy number of the HER2 gene in cells obtained from a dog urine sample as an indicator.
Prior Art Documents
Patent Documents
[0003]
Patent Document 1
Summary of the Invention
Problems to be Solved by the Invention
[0004] However, even in view of such patent documents, it cannot be said that technologies contributing to early detection of cancer in Carnivora animals have been sufficiently provided. The present invention has been made to solve such problems, and an object of the present invention is to provide a technology that can contribute to the diagnosis of cancer in Carnivora animals, and can inexpensively and rapidly test for the possibility of cancer development without imposing stress on the animals.
Means for Solving the Problems
[0005] As a result of diligent research, the inventors have found that Bacteroides fragilis is increasing in various types of cancer, regardless of the specific cancer species, in carnivorous animals. Furthermore, they found that while the increase in this bacterial species cannot be detected using the amount of the bft gene as an indicator, it correlates with the amount of the carbohydrate hydrolase family 20 (GH20) gene, and that cancer can be detected using the amount of the GH20 gene as an indicator.
[0006] Furthermore, in carnivores, we found that pks islands are increased in various types of cancer, regardless of the cancer type, and that cancer can be detected using the amount of genes constituting pks islands as an indicator. Based on these findings, we completed the following inventions.
[0007] (1) A first aspect of the method for testing cancer in carnivorous animals according to the present invention includes detecting the amount of the GH20 gene derived from Bacteroides fragilis in a sample from a test animal.
[0008] (2) A second aspect of the method for testing cancer in carnivorous animals according to the present invention includes detecting the amount of genes constituting pks islands in a sample from a test animal.
[0009] (3) In the present invention, the carnivorous animal may be a canid or a felid.
[0010] (4) In the present invention, the GH20 gene derived from Bacteroides fragilis may contain a DNA sequence that has 90% or more sequence identity with SEQ ID NO: 19.
[0011] (5) A first embodiment of the diagnostic marker for cancer in carnivorous animals according to the present invention comprises the GH20 gene derived from Bacteroides fragilis.
[0012] (6) A second embodiment of the diagnostic marker for cancer in carnivorous animals according to the present invention includes genes that constitute pks islands.
[0013] (7) A first embodiment of the cancer testing kit for carnivorous animals according to the present invention includes a PCR primer set capable of amplifying the GH20 gene derived from Bacteroides fragilis.
[0014] (8) A second embodiment of the cancer testing kit for carnivorous animals according to the present invention includes a PCR primer set capable of amplifying genes constituting pks islands.
[0015] (9) A first aspect of a method for screening for cancer prevention or improvement agents for carnivorous animals according to the present invention comprises detecting the amount of the GH20 gene derived from Bacteroides fragilis in a sample.
[0016] (10) A second aspect of the method for screening for cancer prevention or improvement agents for carnivorous animals according to the present invention includes detecting the amount of genes constituting pks islands in a sample. [Effects of the Invention]
[0017] According to one embodiment of the present invention, it is possible to test for the likelihood that carnivorous animals are suffering from cancer.
[0018] According to one embodiment of the present invention, cancer can be detected using non-invasive or minimally invasive biological samples such as feces, saliva, blood, and bodily fluids, while reducing the burden of hospital visits and the physical and mental burden associated with examinations on the test animals and their owners.
[0019] The amount of the GH20 gene derived from Bacteroides fragilis, or the amount of genes constituting pks islands, can be measured by PCR. In one embodiment of the present invention, comprehensive analysis of the gut microbiota is unnecessary, thus enabling rapid and inexpensive cancer testing.
[0020] According to one embodiment of the present invention, since cancer in Carnivora animals can be tested for, it can contribute to the diagnosis of the relevant disease, and in turn, can contribute to early detection of cancer, prompt initiation of treatment, improvement of treatment outcomes, and enhancement of the quality of life of companion animals and their owners.
[0021] According to one embodiment of the present invention, it is possible to screen for a substance that reduces the likelihood of developing cancer in Carnivora animals or ameliorates the medical condition, that is, a preventive or ameliorating agent for cancer. The agent extracted in this manner can be expected to prevent or ameliorate cancer in Carnivora animals, or maintain their health. [Brief Description of the Drawings]
[0022] [Figure 1] This is a diagram showing the structure of the pks island, and is cited from Figure 1 of Reference 1 (Takayuki Kamitakara, Doctoral Dissertation: Study on the Association of Escherichia coli in the Human Intestinal Tract with Colorectal Cancer and Adenoma, The University of Tokyo, 2016). [Figure 2] This is a table showing the attributes and the like of 29 dogs with cancer (DC1 to 29, disease group) and 20 healthy dogs (DH1 to 20, healthy group). [Figure 3] This is a table showing the attributes and the like of 5 cats with cancer (CC1 to 5, disease group) and 16 healthy cats (CH1 to 16, healthy group). [Figure 4](a) is a bar graph showing the average value of the presence ratio of the bft gene in dogs of the healthy group and the disease group. (b) is a bar graph showing the average value of the presence ratio of the bft gene in cats of the healthy group and the disease group. (c) is a bar graph showing the average value of the presence ratio of the GH20 gene in dogs of the healthy group and the disease group. (d) is a bar graph showing the average value of the presence ratio of the GH20 gene in cats of the healthy group and the disease group. (e) is a bar graph showing the average value of the presence ratio of the clbN gene in dogs of the healthy group and the disease group. (f) is a bar graph showing the average value of the presence ratio of the clbN gene in cats of the healthy group and the disease group. (g) is a bar graph showing the sum of the average values of the presence ratios of the GH20 gene and the clbN gene (GH20+ClbN) in dogs of the healthy group and the disease group. (h) is a bar graph showing GH20+ClbN in cats of the healthy group and the disease group. [Mode for Carrying Out the Invention]
[0023] Hereinafter, the present invention will be described in detail.
[0024] Carnivora, also called the feline order, is classified into the Caniformia suborder and the Feliformia suborder. Examples of animals belonging to the Caniformia suborder include Canidae, Ailuridae, Procyonidae, Mustelidae, Mephitidae, Ursidae, Otariidae, Odobenidae, and Phocidae. Examples of animals belonging to the Feliformia suborder include Nandiniidae, Felidae, Prionodontidae, Viverridae, Hyaenidae, Eupleridae, and Herpestidae.
[0025] Cancer is a disease in which a malignant tumor develops in any tissue, organ, or cell of the body. Depending on the type of cell in which it originates, cancer can be classified into carcinoma (cancer that originates in epithelial cells, such as colorectal cancer, lung cancer, stomach cancer, breast cancer, prostate cancer, pancreatic cancer, and hepatocellular carcinoma), sarcoma (cancer that originates in cells that make up bone and muscle, such as osteosarcoma, chondrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and leiomyosarcoma), and hematopoietic malignancies (cancer that originates in cells in blood vessels, bone marrow, and lymph nodes, such as white blood cells and lymphocytes, such as leukemia, malignant lymphoma, and multiple myeloma). The present invention may target any of these cancers.
[0026] In the present invention, "cancer testing" includes tests to determine whether the test animal is likely or unlikely to have cancer, and tests to make a definitive diagnosis if the test animal already has cancer.
[0027] Bacteroides fragilis is a non-spore-forming, Gram-negative, obligate anaerobic rod-shaped bacterium that is commensal to the lumen of the human digestive tract. This bacterium has the property of decomposing mucin in the lumen of the host digestive tract and utilizing it as a carbon source, and possesses genes encoding multiple carbohydrate hydrolases (GH), such as GH29, GH2, GH18, and GH20. Carbohydrate hydrolases are classified as EC number 3.2.1- and are a large enzyme class classified as the GH family of 187 (as of December 2023) in the Carbohydrate-Active enZymes (CAZy) database. In the first aspect of the present invention, the amount of the gene encoding GH20 (GH20 gene) of this bacterium is detected. GH20 is a β-N-acetylglucosaminidase involved in the degradation of mucin core 3 (GlcNAcβ1-3GalNAcα1-Ser / Thr) and Type-2 LacNAc (Galβ1-4GlcNAcβ1-R) (Norihiko Kato, Takamine Katayama, Mucin Degradation Mechanism of Intestinal Bacteria, Glycoforum. 2023 Vol.27 (1), A3) DOI: https: / / doi.org / 10.32285 / glycoforum.27A3J) (Glover, JS, Ticer, TD & Engevik, MA Characterizing the mucin-degrading capacity of the human gut microbiota. Sci Rep 12, 8456 (2022). https: / / doi.org / 10.1038 / s41598-022-11819-z).
[0028] The pks island is a group of genes found in Escherichia coli, consisting of approximately 54,000 base pairs (about 1% of the entire E. coli genome). It has the structure shown in Figure 1 and contains multiple genes, including three nonribosomal peptide megasynthases (NRPS) (clbH, clbJ, clbN), three polyketide megasynthases (PKS) (clbC, clbI, clbO), and two hybrid NRPS / PKS megasynthases (clbB, clbK). The final product generated by each enzyme encoded in the pks island is presumed to be a complex of peptide and polyketide, and has been named colibactin. Polyketide refers to a compound having a polyketone chain, produced using acetyl-CoA as the starting material and malonyl-CoA as the extension material. It has been reported that pks islands are present not only in Escherichia coli but also in some bacteria such as Klebsiella pneumoniae (Reference 1). In a second aspect of the present invention, a portion or all of the pks islands, for example, the amount of one or more genes selected from the above-mentioned plurality of genes, is detected.
[0029] In the present invention, examples of samples include those that reflect the bacterial flora in the living organism of the test animal. Specifically, examples include feces, intestinal contents, washing fluids and bodily fluids (saliva, mucus, lymph, etc.) collected in connection with examinations such as endoscopy, mucous membrane of the gastrointestinal lumen, tissue or cells collected or excised by surgery, blood, skin, cultured intestinal models, etc.
[0030] As shown in the examples described later, the amount (proportion) of the GH20 gene derived from Bacteroides fragilis in feces shows a correlation with carnivorous animals suffering from cancer, being higher than in individuals without the disease. In other words, there is a positive correlation between the amount of the GH20 gene and the likelihood of developing cancer. Therefore, the GH20 gene derived from Bacteroides fragilis can be used as a diagnostic marker for cancer. That is, by detecting the amount of the GH20 gene derived from Bacteroides fragilis, the likelihood of developing cancer in carnivorous animals can be examined.
[0031] Furthermore, as shown in the examples described later, the amount (proportion) of pks islands or the genes that constitute them in feces shows a correlation with carnivorous animals that have cancer, being higher than in individuals without the disease. In other words, there is a positive correlation between the amount of genes that constitute pks islands (pks island constituent genes, such as clbH, clbJ, clbN, clbC, clbI, clbO, clbB, clbK, etc.) and the likelihood of developing cancer. Therefore, pks island constituent genes can be used as a diagnostic marker for cancer. That is, the likelihood of developing cancer in carnivorous animals can be examined by detecting the amount of pks island constituent genes.
[0032] Furthermore, based on the above correlation, it can be said that "substances that reduce the amount of the GH20 gene derived from Bacteroides fragilis" or "substances that reduce the amount of pks island constituent genes" reduce the likelihood of developing cancer in carnivorous animals, or prevent the worsening of the disease, or even improve it.
[0033] Therefore, cancer preventive or ameliorative agents for carnivorous animals can be screened using the amount of the "GH20 gene derived from Bacteroides fragilis" or "pks island constituent genes" as indicators. In this screening method, for example, the test substance can be added to a cultured intestinal tract model, or the test substance can be administered to test animals, and the amount of the gene can be detected after a certain period of time. If a substance that reduces the amount of the GH20 gene or the amount of pks island constituent genes is extracted using this test system, it can be said to be a substance that reduces the likelihood of developing cancer in carnivorous animals or improves the disease condition, i.e., a cancer preventive or ameliorative agent.
[0034] More specifically, the screening method may include, for example, the steps of: measuring the amount of "GH20 gene derived from Bacteroides fragilis" or "pks island constituent gene" in a sample before administration of the test substance; measuring the amount of "GH20 gene derived from Bacteroides fragilis" or "pks island constituent gene" in a sample after administration of the test substance; and selecting a test substance useful as a cancer preventive or ameliorative agent based on the measurement results of the samples before and after administration.
[0035] The DNA sequence of the GH20 gene from Bacteroides fragilis is available from known databases. Examples of such DNA sequences include, for example, Sequence ID No. 5 below, or sequences with relatively high sequence identity to Sequence ID No. 5. [SEQ ID NO: 5] GH20 gene from Bacteroides fragilis strain CCUG4856T (length 2073 residues), accession number: CP036555.1 (genome): 3048981-3051053 (GH20 region) ATGATAAAACCTACAATGAGAATTTGTACTTTCTTGCTTGCAGCCGGTTTGATGATAGCAACAGCTGGTATGAAAGCGCAGTCTGTCATTCCCATACCTCTCCAGATGGAACAAGGAAGCGGAACTTTTCAATTTTCCG GTGAAACCCTGTTGTATACCAATCTGAAG GGTAAGGAGAAGAAAATGATGATGGATTATCTGGAGACATTACCCATTCACTTTAAAAGTTCCAAAAAACAAGCCAAAGAGAATGTAGTCTCATT GCTGATAACAAAGGATAACTCTCAGTTACCC
[0036] Furthermore, the GH20 gene may also be a gene containing the DNA sequence of SEQ ID NO: 17, or a DNA sequence with relatively high sequence identity to SEQ ID NO: 17. Here, SEQ ID NO: 17 is the sequence from positions 169 to 263 of SEQ ID NO: 5. [Sequence ID 17] (length 95 residues) Region PP of the GH20 gene GGTAAGGAGAAGAAAATGATGATGGATTATCTGGAGACATTACCCATTCACTTTAAAAGTTCCAAAAAACAAGCCAAAGAGAATGTAGTCTCATT
[0037] The DNA sequences of pks islands, or the DNA sequences of pks island constituent genes, are available from known databases. Examples of such DNA sequences include the clbA, clbB, clbC, clbD, clbE, clbF, clbG, clbH, clbI, clbJ, clbK, clbL, clbM, clbN, clbO, clbP, clbQ, and clbS genes (SEQ ID NOs. 31-48) derived from the pks colibactin polyketide biosynthesis gene cluster (GenBank: OM103703.1) of Escherichia coli strain KS_P003, or sequences with relatively high sequence identity to SEQ ID NOs. 31-48. [SEQ ID NO: 31] clbA gene (length 735 residues), GenBank: OM103703.1, residues 1-735 [SEQ ID NO: 32] clbB gene (length 9621 residues), GenBank: OM103703.1, residues 1390-11010 [SEQ ID NO: 33] clbC gene (length 2601 residues), GenBank: OM103703.1, residues 11051-13651 [SEQ ID NO: 34] clbD gene (length 867 residues), GenBank: OM103703.1, positions 13664-14530 [SEQ ID NO: 35] clbE gene (length 249 residues), GenBank: OM103703.1, positions 14560-14808 [SEQ ID NO: 36] clbF gene (length 1131 residues), GenBank: OM103703.1, residues 14812-15942 [SEQ ID NO: 37] clbG gene (length 1269 residues), GenBank: OM103703.1, positions 15939-17207 [SEQ ID NO: 38] clbH gene (length 4797 residues), GenBank: OM103703.1, residues 17255-22051 [SEQ ID NO: 39] clbI gene (length 3033 residues), GenBank: OM103703.1, residues 22101-25133 [SEQ ID NO: 40] clbJ gene (length 6501 residues), GenBank: OM103703.1, residues 25177-31677 [SEQ ID NO: 41] clbK gene (length 6465 residues), GenBank: OM103703.1, residues 31688-38152 [SEQ ID NO: 42] clbL gene (length 1464 residues), GenBank: OM103703.1, residues 38145-39608 [SEQ ID NO: 43] clbM gene (length 1440 residues), GenBank: OM103703.1, residues 39670-41109 [SEQ ID NO: 44] clbN gene (length 4368 residues), GenBank: OM103703.1, residues 41106-45473 [SEQ ID NO: 45] clbO gene (length 2460 residues), GenBank: OM103703.1, residues 45504-47963 [SEQ ID NO: 46] clbP gene (length 1506 residues), GenBank: OM103703.1, positions 47985-49490 [SEQ ID NO: 47] clbQ gene (length 723 residues), GenBank: OM103703.1, positions 49483-50205 [SEQ ID NO: 48] clbS gene (length 513 residues), GenBank: OM103703.1, residues 50240-50752
[0038] Furthermore, the pks island constituent genes may also be genes containing the DNA sequence of SEQ ID NO: 49, or a DNA sequence with relatively high sequence identity with SEQ ID NO: 45. Here, SEQ ID NO: 45 is the sequence from positions 223 to 582 of SEQ ID NO: 44. [SEQ ID NO: 49] (360 residues in length) Region QQ of the clbN gene CAGCCTTATCACTGGCGCGATATCCGCCATTTGACTTTTTCCCCAGATTATGACAAGGAGAACCTACGCCCAGCGGCGATCGAAACATTTGTTGATGAGTGGTTCGGCAGCCCTTTACCCTGCTGGCGCACGATTTGTTCGAGTTTGTCACCTTTACGTGCGGTGAACAATACAGCGGT TATTTATTTAAAGCCCATCACGGCATTGCTGATGGTTGGTCAATGGCGTTGTTGTCAAACCATGTCAAGCGAGCATACGAACAGCAGGACGTACCAGATGATGCGTCACCAGCCTATAGCGCATTTCTGGCGCAGCAGCAATCTTATCAGGCGTCAACGCGCTTTGCCGTTGATCGTGGC
[0039] Here, when we refer to a "DNA sequence with high sequence identity," examples of sequence identity values include 70% or higher, 71% or higher, 72% or higher, 73% or higher, 74% or higher, 75% or higher, 76% or higher, 77% or higher, 78% or higher, 79% or higher, 80% or higher, 85% or higher, 90% or higher, 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, 99% or higher, and 100% or higher. Note that "sequence identity" refers to sequence consistency and is used interchangeably with "identity."
[0040] A "DNA sequence with high sequence identity" can also be defined as "a DNA sequence in which one or more nucleotides are deleted, substituted, inserted, or added." In this case, the number of nucleotides deleted, substituted, inserted, or added can be, for example, 1-621, 1-601, 1-580, 1-559, 1-538, 1-518, 1-497, 1-476, 1-456, 1-435, 1-414, 1-310, 1-207, 1-186, 1-165, 1-145, or 1-124. Examples include 1-103 items, 1-82 items, 1-62 items, 1-41 items, 1-30 items, 1-29 items, 1-28 items, 1-27 items, 1-26 items, 1-25 items, 1-24 items, 1-23 items, 1-22 items, 1-21 items, 1-20 items, 1-19 items, 1-18 items, 1-17 items, 1-16 items, 1-15 items, 1-14 items, 1-11 items, 1-7 items, and 1-3 items.
[0041] Sequence identity with a given DNA sequence can be confirmed according to standard methods, for example, using programs such as FASTA (http: / / www.genome.JP / tools / fasta / ), BASIC local alignment search tool (BLAST; http: / / www.ncbi.nlm.nih.gov.), Position-Specific Iterated BLAST (PSI-BLAST; http: / / www.ncbi.nlm.nih.gov.), CLUSTALW (http: / / www.genome.jp / ja / ), and MAFFT (http: / / www.genome.jp / ja / ).
[0042] The amount of the GH20 gene or pks island constituent genes can be detected by known standard methods. For example, when the sample is feces, a "shotgun sequencing method" can be used for the whole genomic DNA of bacteria extracted from the fecal sample. In this method, the genomic DNA is first cut with restriction enzymes, and the sequences of the resulting short DNA strands are determined. The fragments are cut and sequenced in such a way that they overlap. Finally, the overlapping parts of the DNA fragment sequences are joined together on a computer to determine the long sequence. While this method is relatively costly in terms of time and expense, it allows for accurate determination of the type and quantity of genes.
[0043] Alternatively, one could exemplified a method involving "performing PCR using specific primers" on the whole genomic DNA of bacteria extracted from a sample. The PCR method allows for the rapid and inexpensive detection of the amount of GH20 genes or pks island constituent genes. The PCR reaction conditions can be appropriately set depending on the type and preparation method of the sample, the sequence and length of the primers, and the type and properties of the enzymes used in the reaction.
[0044] Specific primers for GH20 gene amplification used in PCR can be designed based on some or all of the DNA sequences of known GH20 genes (e.g., SEQ ID NOs. 5-12, 17). More specifically, examples of specific primers include the primer sets (SEQ ID NOs. 15, 16) described in the examples below. In SEQ ID NO. 5, the sequences corresponding to SEQ ID NOs. 15 and 16 are indicated by the underlined portion.
[0045] Specific primers for amplifying pks island constituent genes used in PCR can be designed based on the DNA sequences of some or all known pks island constituent genes. More specifically, examples of specific primers include the primer set described in the examples below (clbN gene amplification primers; SEQ ID NOs. 18, 19). Other primer sets listed below can also be exemplified. <<Primers for clbB gene amplification (Source: Arthur, 2013)>> Forward primer: 5'-GCGCATCCTCAAGAGTAAATA-3' (SEQ ID NO: 50) Reverse primer: 5'-GCGCTCTATGCTCATCAACC-3' (SEQ ID NO: 51) ≪ClbQ gene amplification primer (Source: Reference 1)≫ Forward primer: 5'-GCACGATCGGACAGGTTAAT-3' (SEQ ID NO: 52) Reverse primer: 5'-TAGTCTCGGAGGGATCATGG-3' (SEQ ID NO: 53) ≪ClbA gene amplification primer (Source: Reference 1)≫ Forward primer: 5'-AAGCCGTATCCTGCTCAAAA-3' (SEQ ID NO: 54) Reverse primer: 5'-GCTTCTTTGAGCGTCCACAT-3' (SEQ ID NO: 55) ≪ClbP gene amplification primer (Source: Reference 1)≫ Forward primer: 5'-GGCCGCAAAGTAATATTGTCC-3' (SEQ ID NO: 56) Reverse primer: 5'-CGTTGTTGCTGTGTTTTTGGG-3' (SEQ ID NO: 57) ≪ClbP gene amplification primer (Source: Reference 1)≫ Forward primer: 5'-GCGATAAACACGGAAAGCAC-3' (SEQ ID NO: 58) Reverse primer: 5'-TCGGCTGGAAAACCCTATG-3' (SEQ ID NO: 59) ≪ClbP gene amplification primer (Source: Reference 1)≫ Forward primer: 5'-CCCGTCACATTTTCAATCACC-3' (SEQ ID NO: 60) Reverse primer: 5'-CGTGAGCACAGTGAATTTATCTCC-3' (SEQ ID NO: 61)
[0046] In other words, the present invention provides a cancer testing kit for carnivorous animals and a screening kit for cancer prevention and improvement agents for carnivorous animals, comprising a "PCR primer set capable of amplifying part or all of the GH20 gene derived from Bacteroides fragilis" or a "PCR primer set capable of amplifying part or all of the pks island constituent genes." The kit may further include enzymes necessary for the PCR reaction, such as dNTPs and DNA polymerase, a sample collection device, a labeling substance, a reaction buffer, a washing buffer, a positive control, a negative control, and instructions such as criteria for determining pancreatic cancer and operating procedures.
[0047] In a sample, a low amount of the "GH20 gene derived from Bacteroides fragilis" or "pks island constituent gene" suggests a low likelihood of developing cancer, or that the test substance has a preventive or ameliorative effect on cancer. However, since the amount of genes and bacteria purified from samples such as feces (purification efficiency) is not constant, it is preferable to calculate the proportion of the total number of bacteria and make a judgment based on that proportion.
[0048] Based on the detection results of the amount of the "GH20 gene derived from Bacteroides fragilis" or the "pks island constituent gene," the reference values for determining the likelihood of developing cancer / whether or not there is a preventive or ameliorative effect can be set as appropriate, and may vary depending on various factors such as the method of measuring the amount of the gene, the method of calculating the reference value, the breed, sex, age, clinical findings, rearing region and environment of the test animals, and the test data accumulated up to that point.
[0049] For example, if the amount of the GH20 gene or pks island constituent genes is detected by PCR, and the value obtained by dividing the "DNA copy number of the gene in question" by the "DNA copy number of the 16S rRNA gene" is defined as the "proportion of the gene in question," then if this proportion is 0.01 or higher, 0.02 or higher, 0.03 or higher, 0.04 or higher, 0.05 or higher, 0.06 or higher, 0.07 or higher, 0.08 or higher, 0.09 or higher, or 0.1 or higher, it can be determined that there is a high probability of having cancer.
[0050] The present invention will be described below based on various examples. The technical scope of the present invention is not limited to the features shown in these examples. [Examples]
[0051] <Test animals> In this example, dogs (domestic dogs of the genus Canis, Canis lupus familiaris) and cats (domestic cats of the genus Felis, Felis catus) were used as test animals. For dogs, 20 healthy dogs (DH1-20) were designated as the control group, and 29 dogs diagnosed with cancer (DC1-29) were designated as the disease group. For cats, 16 healthy cats (CH1-16) were designated as the control group, and 5 cats diagnosed with cancer (CC1-5) were designated as the disease group.
[0052] The disease group consisted of individuals in whom a pathologist made a definitive diagnosis of malignant tumor based on the evaluation of pathological tissue slides obtained from tissue biopsies. The healthy group consisted of individuals in whom no health problems were confirmed through physical and clinical examinations by veterinarians, as well as interviews with their owners. The attributes of the dogs and cats among the test animals are shown in Figure 1 and Figure 2, respectively. As shown in Figures 1 and 2, there were no significant differences in breed, sex, or age between the healthy group and the disease group. Furthermore, the types of cancer in the disease group were diverse.
[0053] <Example 1> Comprehensive Microbial Analysis (1) Recovery of bacterial genomic DNA from feces Fecal samples were collected from the test animals using the fecal collection kit "FS-0017" (Techno Suruga Lab Co., Ltd.). Generally, the types and numbers of bacteria contained in feces are considered to reflect the bacterial flora of the dogs and cats in question. DNA was extracted from the fecal samples using the QIAamp PowerFecal Pro DNA Kit (QIAGEN) according to the attached instructions, and this was defined as total fecal DNA. The DNA concentration was measured using a spectrophotometer ND-1000 (NanDrop Technologies) and the solution was prepared to a concentration of 10 ng / μL.
[0054] (2) 16S rRNA metagenomic analysis Following a previous report (Shunsuke Takahashi, PLosONE, No. 9, Vol. 8, e105592, August 2014), a comprehensive analysis of the types and relative abundances of bacteria contained in feces was performed. Specifically, using total fecal DNA as a template, polymerase chain reaction (PCR) was performed using the Dual-index method (Hisada Takayoshi et al., Arch Microbiol, Vol. 197, No. 7, pp. 919-934, June 2015) with universal primers of Sequence ID No. 1 and 2 below to amplify the V3-V4 region of bacterial 16S rDNA. Forward primer (341f): 5'-CCTACGGGAGGCAGCAG-3' (SEQ ID NO: 1) Reverse primer (R806): 5'-GGACTACHVGGGTWTCTAAT-3' (SEQ ID NO: 2)
[0055] Next, the nucleotide sequences of the PCR amplification products were decoded using the paired-end sequencing method with the next-generation sequencer MiSeq (Illumina). The decoded nucleotide sequences were analyzed using the EzBioCloud 16S database and the 16S microbiome pipeline (EzBioCloud 16S-based MTP app, https: / / www.EZbiocloud.net) to identify the classification at the genus or species level and determine their relative abundance. The relative abundance was calculated as the percentage of reads for each bacterial species (genus) relative to the total number of reads. For the relative abundance in each test individual, the mean value was calculated for each group (disease group or healthy group), and the groups were compared using a one-sided parametric test to determine the p-value. The results are shown in Table 1. [Table 1]
[0056] As shown in Table 1, Bacteroides fragilis was significantly more abundant in the diseased group and less abundant in the healthy group in both dogs and cats. In other words, it was revealed that Bacteroides fragilis is increased in various types of cancer in carnivores, regardless of the type of cancer. In cats, the Escherichia coli group (Escherichia coli, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Shigella boydii, Escherichia fergusonii, Escherichia marmotae, LFHY_s, and KE701379_s) was significantly more abundant in the diseased group and less abundant in the healthy group. In other words, it was revealed that the Escherichia coli group is increased in various types of cancer in cats, regardless of the type of cancer. No significant difference in the proportion of the Escherichia coli group was observed between the diseased group and the healthy group in dogs.
[0057] <Example 2> Quantitative PCR (1) Primers for quantifying the bft gene Bacteroides fragilis exists in both toxic and non-toxic forms, and the toxic form has been reported to be involved in the development of human colorectal cancer. The toxic form possesses the bft gene and produces the toxin BFT (Bacteroides Fragilis Toxin, a 20kDa zinc-dependent metalloproteinase), which is the gene product of this gene. BFT promotes the survival, proliferation, and DNA damage of cancer cells through interaction with epithelial cells and damage to E-cadherins. On the other hand, the non-toxic form does not possess the bft gene (see Reference 1). For this reason, conventionally, the detection of the bft gene has been used as an indicator to detect B. fragilis, which is considered to be the causative agent of colorectal cancer (see Reference 2). *Reference 1: Cheng WT, Kantilal HK, Davamani F. The mechanism of Bacteroides fragilis toxin contributes to colon cancer formation. Malays J Med Sci. 2020;27(4):9?21. https: / / doi.org / 10.21315 / mjms2020.27.4.2 *Reference 2: Purcell, R., Pearson, J., Frizelle, F. et al. Comparison of standard quantitative, and digital PCR in the detection of enterotoxigenic Bacteroides fragilis. Sci Rep 6, 34554 (2016). https: / / doi.org / 10.1038 / srep34554
[0058] Therefore, based on the results showing a significant increase in Bacteroides fragilis in dogs and cats in Example 1, the following primers, described in Reference 2, were prepared as specific primers capable of amplifying partial sequences of the bft gene in order to quantitatively detect the bft gene in the test animals. ≪Primers for BFT gene amplification≫ Forward primer; 5'- GGATACATCAGCTGGGTTGTAG-3' (SEQ ID NO: 3) Reverse primer; 5'-GCGAACTCGGTTTATGCAGT-3'(SEQ ID NO: 4)
[0059] (2) Primers for quantifying the GH20 gene Bacteroides fragilis is a mucin-degrading bacterium that breaks down mucin, which plays a role in protecting the mucus layer of the host's digestive tract, and utilizes it as a carbon source. On the other hand, mucin changes in its glycosylation pattern and expression level during cancer development, affecting cell proliferation, differentiation, transformation, adhesion, invasion, and immune surveillance (Hollingsworth, M., Swanson, B. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4, 45-60 (2004). https: / / doi.org / 10.1038 / nrc1251).
[0060] Therefore, the inventors of this application became interested in the relationship between mucin-degrading enzymes of Bacteroides fragilis and cancer, and decided to quantitatively analyze the genes of the carbohydrate hydrolase family 20 (GH20) of this bacterium. The GH20 gene encodes β-N-acetylglucosaminidase. This enzyme is involved in the degradation of mucin core 3 (GlcNAcβ1-3GalNAcα1-Ser / Thr) and Type-2 LacNAc (Galβ1-4GlcNAcβ1-R) (Norihiko Kato, Takamine Katayama, Mucin Degradation Mechanism of Intestinal Bacteria, Glycoforum. 2023 Vol.27 (1), A3) DOI: https: / / doi.org / 10.32285 / glycoforum.27A3J) (Glover, JS, Ticer, TD & Engevik, MA Characterizing the mucin-degrading capacity of the human gut microbiota. Sci Rep 12, 8456 (2022). https: / / doi.org / 10.1038 / s41598-022-11819-z).
[0061] The following primers were designed to specifically amplify the GH20 gene of Bacteroides fragilis. First, the DNA sequences of the GH20 gene from eight strains of Bacteroides fragilis (SEQ ID NOs. 5-12) and the DNA sequences of the GH20 gene from two strains of Bacteroides thetaiotaomicron (SEQ ID NOs. 13, 14) were aligned. In this alignment, a sequence region conserved in Bacteroides fragilis but not in Bacteroides thetaiotaomicron (Fragilis-conserved region) was identified. Based on the Fragilis-conserved region, the following primers were designed. Primers for amplifying the GH20 gene in Bacteroides fragilis Forward primer; 5'-GTGAAACCCTGTTGTATACCAATCTGAAG -3' (SEQ ID NO: 15) Reverse primer; 5'-GGGTAACTGAGAGTTATCCTTTGTTATCAGC-3' (SEQ ID NO: 16)
[0062] Here, for example, using the DNA sequence of the GH20 gene of Bacteroides fragilis ATCC strain CCUG4856T (SEQ ID NO: 5) as a reference, SEQ ID NO: 15 corresponds to positions 140-168 in SEQ ID NO: 5, and SEQ ID NO: 16 corresponds to positions 264-294 in SEQ ID NO: 5. In other words, the above primer set amplifies the portion corresponding to 155 nucleotides from positions 140-294 in SEQ ID NO: 5. In this invention, the portion of the GH20 gene corresponding to positions 140-294 (155 nucleotides) in SEQ ID NO: 5 is sometimes referred to as "region P". Furthermore, the portion of region P excluding the primer portions of SEQ ID NOs: 15 and 16, corresponding to positions 169-263 (95 nucleotides, SEQ ID NO: 17) in SEQ ID NO: 5 is sometimes referred to as "region PP".
[0063] (3) Primers for quantifying the clbN gene colibactin, produced by some E. coli strains, is a toxin that exhibits toxicity by cleaving the double helix of DNA in animal cells and halting the cell cycle, and has been linked to human colorectal cancer. Colibactin is biosynthesized by a group of genes called the clb cluster located on pks islands of E. coli (Yuichi Hirayama, Kenji Watanabe, Commentary: Complete elucidation of the chemical structure of "colibactin," a carcinogenic risk factor produced by E. coli: Detection and structural determination of a trace and unstable unknown natural product, Chemistry and Biology 60(3): 123-130 (2022)).
[0064] Therefore, based on the result that the E. coli group was significantly increased in the cats in Example 1, the following specific primers were prepared to quantitatively detect pks islands in the test animals, which can amplify partial sequences of the clbN gene present in pks islands (Solis-Marcano NE, Morales-Cruz M, Vega-Hernandez G, Gomez-Moreno R, Binder C et al. PCR-assisted impedimetric biosensor for colibactin-encoding pks genomic island detection in E. coli samples. Analytical and Bioanalytical Chemistry 2021;413(18):4673-4680. DOI: 10.1007 / s00216-021-03404-6). <<Primers for clbN gene amplification>> Forward primer; 5'- GTGAAGTGGTCAGCCAAGTG -3' (SEQ ID NO: 18) Reverse primer; 5'-TCGATATAGTCACGCCACCA-3' (SEQ ID NO: 19)
[0065] Here, for example, using the DNA sequence of the clbN gene in the pks colibactin polyketide biosynthesis gene cluster (GenBank: OM103703.1) of Escherichia coli strain KS_P003 (SEQ ID NO: 44; 41106-45473, 4368 nucleotides long in OM103703.1) as a reference, SEQ ID NO: 18 corresponds to positions 203-222 in SEQ ID NO: 44, and SEQ ID NO: 19 corresponds to positions 583-602 in SEQ ID NO: 44. In other words, according to the above primer set, the portion corresponding to positions 202-602 (401 nucleotides) in SEQ ID NO: 44 is amplified. In the present invention, the portion of the clbN gene corresponding to positions 202-602 (401 nucleotides) in SEQ ID NO: 44 is sometimes referred to as "region Q". Furthermore, within region Q, the portion corresponding to positions 223-582 (360 nucleotides, corresponding to sequence number 49) in sequence number 44, excluding the primer portions of sequence numbers 18 and 19, is sometimes referred to as "region QQ".
[0066] (4) Universal Primer The following universal primers were prepared to amplify the V3-V4 region of the 16S ribosomal RNA (16S rRNA) gene in all bacteria. ≪For amplifying the 16S rRNA (V3-V4 region) gene in all bacteria≫ Forward primer; 5'-CGGTGAATACGTTCCCGG-3' (SEQ ID NO: 20) Reverse primer; 5'- TACGGCTACCTTGTTACGACTT -3' (SEQ ID NO: 21)
[0067] (5) Quantitative PCR Using the total fecal DNA of the test individuals in Example 1(1) as a template, quantitative PCR was performed using the quantitative PCR reagent "PowerTrack SYBR Green Master Mix" (Thermo Fisher Scientific) and the primers of Examples 2(1) to (4), and the DNA copy number of each gene subsequence was determined. The PCR reaction was performed by holding at 95°C for 2 minutes, followed by 40 cycles of 10 seconds at 95°C, 15 seconds at 60°C (bft gene, GH20 gene, 16S rRNA gene) or 55°C (clbN gene), and 15 seconds at 72°C (GH20 gene, 16S rRNA gene), 20 seconds (bft gene), or 30 seconds (clbN gene), and finally an extension reaction at 72°C for 1 minute.
[0068] Next, the number of DNA copies of each gene (bft gene, GH20 gene, clbN gene) per 1 mL of template DNA solution was divided by the number of DNA copies of the 16S rRNA gene to calculate the relative abundance of each gene. For the clbN gene, since it is often located in a plasmid and multiple copies are present per strain, the relative abundance was calculated by dividing the number of DNA copies of the bft gene by the number of DNA copies of the 16S rRNA gene, and then dividing by 2. The mean relative abundance of each gene was calculated for each group, and the difference between groups was examined using the Mann-Whitney U test with GraphPad Prism v.9.5.1, with P < 0.05 considered statistically significant (*P < 0.05, **P < 0.01, ****P < 0.0001). For the GH20 gene and clbN gene, the mean relative abundance of both (GH20 + ClbN) was also calculated for each group and tested similarly. The relative abundances of the bft gene are shown in Figures 3(a) and (b), the relative abundances of the GH20 gene in Figures 3(c) and (d), the relative abundances of the ClbN gene in Figures 3(e) and (f), and the relative abundances of GH20 + ClbN in Figures 3(g) and (h).
[0069] (6) Results of the bft gene As shown in Figure 4(a), the prevalence of the bft gene was below the detection limit in most individuals in both the healthy and diseased groups of dogs, and there was no significant difference between the two groups. As shown in Figure 4(b), in cats as well, the prevalence was below the detection limit in most individuals in both the healthy and diseased groups, and there was no significant difference between the two groups.
[0070] Furthermore, based on the DNA sequences of the bft gene of Bacteroides fragilis (SEQ ID NOs. 22-28), we designed the following SEQ ID NOs. 29 and 30 as primer sets for amplifying the bft gene, consisting of sequences different from SEQ ID NOs. 3 and 4. When quantitative PCR was performed as described in Example 2(5), similar results were obtained. ≪Primers for BFT gene amplification≫ Forward primer; 5'-CGTCAGGTACATGTTTCTATGGATAAGCG-3' (SEQ ID NO: 29) Reverse primer; 5'-CATTTGCGCTTCCTTGTATGCG-3' (SEQ ID NO: 30)
[0071] In other words, no increase in the proportion of the bft gene was observed in cancerous dogs and cats. This suggests that while Bacteroides fragilis is increased in canine and feline cancers, the bft gene is not increased, indicating that cancer is independent of the toxin BFT. Furthermore, it became clear that the bft gene does not function as an indicator for detecting the amount of Bacteroides fragilis to assess the susceptibility to cancer in carnivorous animals such as dogs and cats.
[0072] (7) Results of the GH20 gene As shown in Figure 4(c), the relative abundance of the GH20 gene in dogs was low in most individuals in the healthy control group, while it was high in many individuals in the diseased group. The mean relative abundance was 0.39 in the healthy control group and 2.57 in the diseased group, which was significantly higher (P<0.0001) in the diseased group than in the healthy control group.
[0073] Furthermore, as shown in Figure 4(d), the relative abundance of the GH20 gene in cats was low in almost all individuals in the healthy group, while it was high in many individuals in the diseased group. The average relative abundance was 0.01 in the healthy group and 0.66 in the diseased group, indicating a tendency for the relative abundance to be higher in the diseased group than in the healthy group.
[0074] In other words, in dogs and cats with cancer, the amount of the GH20 gene was increased compared to healthy individuals. Furthermore, as shown in Figures 2 and 3, only four dogs (DC8, DC21, DC23, DC27) had cancer in the intestinal tract, while individuals in the other disease groups had cancer in locations other than the intestinal tract. That is, the amount of the GH20 gene was significantly increased in dogs and cats with cancer in various internal and external body parts, where it is unlikely that Bacteroides fragilis would have an influence. From these results, it has become clear that the amount of the GH20 gene derived from Bacteroides fragilis can serve as an indicator for determining the likelihood of developing cancer in carnivorous animals such as dogs and cats. The causes of cancer are inherently diverse, and the causes are thought to differ depending on the location of development. Given this common technical knowledge, the fact that the GH20 gene can be used as an indicator for determining the likelihood of developing a wide range of cancers, regardless of the type, is a remarkable effect.
[0075] (8) Results of the ClbN gene As shown in Figure 4(e), the prevalence of the ClbN gene in dogs was low in most individuals in the healthy control group, while it was high in many individuals in the diseased group. The mean prevalence was 0.73 in the healthy control group and 2.52 in the diseased group, with the diseased group being significantly higher (P<0.0092) than the healthy group.
[0076] Furthermore, as shown in Figure 4(f), the relative abundance of the ClbN gene in cats was low in almost all individuals in the healthy group, while it was high in many individuals in the diseased group. The average relative abundance was 0.03 in the healthy group and 0.80 in the diseased group, which was significantly higher (P<0.0401) in the diseased group than in the healthy group.
[0077] In other words, despite no significant increase in E. coli observed in cancerous dogs (Example 1), the amount of the ClbN gene was increased in cancerous dogs and cats compared to healthy individuals. Furthermore, as shown in Figures 2 and 3, only four dogs (DC8, DC21, DC23, DC27) had cancer in the intestinal tract, while individuals in the other disease groups had cancer in locations other than the intestinal tract. That is, the amount of the ClbN gene was significantly increased in dogs and cats with cancer in various internal and external body parts that are unlikely to be exposed to colibactin. From these results, it has become clear that the amount of pks island or the amount of each gene constituting pks island can serve as an indicator for judging the susceptibility to a wide range of cancers in carnivorous animals such as dogs and cats. The causes of cancer are inherently diverse, and the causes are thought to differ depending on the location of occurrence. Given this common technical knowledge, the fact that pks island or the genes constituting pks island can serve as an indicator for judging the susceptibility to a wide range of cancers, regardless of the type of cancer, is a remarkable effect.
[0078] (9) Results of GH20+ClbN As shown in Figure 4(g), the relative abundance of GH20+ClbN in dogs was low in most individuals in the healthy control group, while it was high in many individuals in the diseased group. The mean relative abundance was 1.12 in the healthy control group and 5.09 in the diseased group, which was significantly higher (P<0.0001) in the diseased group than in the healthy control group. The P-value was lower than that for evaluation of the GH20 gene alone (Figure 4(c)) and for evaluation of the ClbN gene alone (Figure 4(e)).
[0079] Furthermore, as shown in Figure 4(h), the relative abundance of GH20+ClbN in cats was low in almost all individuals in the healthy group, while it was high in many individuals in the diseased group. The mean relative abundance was 0.04 in the healthy group and 4.45 in the diseased group, which was significantly higher (P<0.0111) in the diseased group than in the healthy group. The P-value was lower than that for evaluation of the GH20 gene alone (Figure 4(d)) and for evaluation of the ClbN gene alone (Figure 4(f)).
[0080] In other words, in dogs and cats with cancer, the amounts of the GH20 gene and the ClbN gene were increased compared to healthy individuals. By evaluating the amounts of these genes together, a higher correlation was observed between the disease group and this increase. From these results, it became clear that the sum of the amounts of the GH20 gene and pks island, or the individual genes constituting the pks island, can serve as a highly accurate indicator for determining the susceptibility to cancer in carnivorous animals such as dogs and cats.
Claims
1. A method for testing cancer in carnivorous animals, comprising detecting the amount of the Bacteroides fragilis-derived carbohydrate hydrolase family 20 (GH20) gene in a sample from a test animal.
2. A method for testing cancer in carnivorous animals, comprising detecting the amount of genes constituting pks islands in a sample from a test animal.
3. The inspection method according to claim 1 or claim 2, wherein the carnivorous animal is a canid or a felid.
4. The testing method according to claim 1, wherein the GH20 gene is a gene containing a DNA sequence with sequence identity of 90% or more with sequence number 19.
5. A cancer diagnostic marker for carnivorous animals, containing the carbohydrate hydrolase family 20 (GH20) gene derived from Bacteroides fragilis.
6. A cancer diagnostic marker for carnivorous animals that contains genes that make up pks island.
7. A cancer screening kit for carnivorous animals, containing a PCR primer set capable of amplifying the carbohydrate hydrolase family 20 (GH20) gene derived from Bacteroides fragilis.
8. A cancer testing kit for carnivorous animals, containing a PCR primer set capable of amplifying the genes that make up pks islands.
9. A method for screening cancer preventive or ameliorative agents for carnivorous animals, comprising detecting the amount of the Bacteroides fragilis-derived carbohydrate hydrolase family 20 (GH20) gene in a sample.
10. A method for screening cancer preventive or ameliorative agents for carnivorous animals, comprising detecting the amount of genes constituting pks islands in a sample.
Citation Information
Patent Citations
Methods for detecting cancer in carnivores
JP7037807B2
